VTRS Viatris
FY2025 10-K
Viatris (VTRS) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Global pharma company delivering generics, branded generics, and innovative medicines to ~1B patients across 165+ countries with 30,000+ employees and 27 manufacturing sites
- • Five positive Phase 3 readouts in 2025: meloxicam acute pain, low-dose estrogen patch (FDA action target July 30, 2026), LYNX-2 night driving (MR-142), VEGA-3 presbyopia (MR-141, FDA action H2 2026), and EFFEXOR Japan GAD
Management Discussion & Analysis
- • Revenue $14.30B, down 3% YoY ($439M decline); Indore facility impact ~$370M drag; Greater China only growth segment, +8% to $2.33B
- • Gross margin 35% vs 38%; adjusted gross margin 56% vs 58%; operating loss $(2.66B) vs near-breakeven $10M in 2024, driven by $2.94B goodwill impairment
Risk Factors
- • FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
- • U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected
Financial SummaryXBRL
Revenue
$14.3B
Net Income
-$3.5B
Gross Margin
35.2%
Operating Margin
-18.7%
Net Margin
-24.7%
ROE
-23.9%
Total Assets
$37.2B
EPS (Diluted)
$-3.00
Operating Cash Flow
$2.3B
Source: XBRL data from Viatris FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Viatris Annual Reports
Get deeper insights on Viatris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.